Osteosarcoma News and Research

RSS
Between two and three percent of all childhood cancers are osteosarcoma. Because osteosarcoma usually develops from osteoblasts, it most commonly affects children and young adults experiencing their adolescent growth spurt. Boys and girls have a similar incidence rate until later in their adolescence, when boys are more commonly affected. While most tumors occur in larger bones, such as the femur, tibia, and humerus, and in the area of the bone that has the fastest growth rate, they can occur in any bone. The most common symptom is pain, but swelling and limited movement can occur as the tumor grows.

Osteosarcoma is an orphan disease with approximately 1,200 new cases diagnosed in the United States each year. A similar incidence of the disease exists in Europe. According to the Children's Oncology Group (COG), the survival of children with osteosarcoma has remained at 60-65 percent since the mid-1980s. The standard treatment for osteosarcoma is tumor resection with combination chemotherapy before and after surgery.
Bone fluoride levels are not associated with osteosarcoma: Study

Bone fluoride levels are not associated with osteosarcoma: Study

First dog enters ADXS-HER2 dose-ranging study in canine osteosarcoma

First dog enters ADXS-HER2 dose-ranging study in canine osteosarcoma

PCIB reports main results of Amphinex Phase I/II study against multiple cancers

PCIB reports main results of Amphinex Phase I/II study against multiple cancers

Eli Lilly, Synthes collaborate to develop osteoinductive products

Eli Lilly, Synthes collaborate to develop osteoinductive products

Mount Sinai researchers identify protein signaling hyperactivity in human sarcoma cells

Mount Sinai researchers identify protein signaling hyperactivity in human sarcoma cells

Lilly's cixutumumab Phase II study results in five subtypes of sarcoma to be presented at 47th ASCO

Lilly's cixutumumab Phase II study results in five subtypes of sarcoma to be presented at 47th ASCO

Reprogrammed herpes virus can improve early cancer diagnosis

Reprogrammed herpes virus can improve early cancer diagnosis

Spectrum receives FDA approval for FUSILEV to treat colorectal cancer

Spectrum receives FDA approval for FUSILEV to treat colorectal cancer

FDA approves Spectrum's FUSILEV Injection to treat metastatic colorectal cancer

FDA approves Spectrum's FUSILEV Injection to treat metastatic colorectal cancer

Research on rare cancers

Research on rare cancers

Rsearchers define new step that controls programmed cell death in cancer cells

Rsearchers define new step that controls programmed cell death in cancer cells

Loss of SKIP sensitizes cancer cells to apoptotic effects of DNA damage-inducing anticancer drugs

Loss of SKIP sensitizes cancer cells to apoptotic effects of DNA damage-inducing anticancer drugs

UCI's doctor, colleagues earn Kappa Delta Ann Doner Vaughan Award for osteosarcoma work

UCI's doctor, colleagues earn Kappa Delta Ann Doner Vaughan Award for osteosarcoma work

HCI creates Pediatric Cancer Late Effects Clinic to help manage long-term issues of treatment

HCI creates Pediatric Cancer Late Effects Clinic to help manage long-term issues of treatment

Researchers to explore genomes of childhood cancers

Researchers to explore genomes of childhood cancers

John Theurer chief to present videos on new limb-sparing surgical techniques at AAOS conference

John Theurer chief to present videos on new limb-sparing surgical techniques at AAOS conference

Spectrum submits FUSILEV sNDA for treatment of colorectal cancer

Spectrum submits FUSILEV sNDA for treatment of colorectal cancer

UH scientist evaluates microRNAs as potential treatment strategy for ovarian cancer

UH scientist evaluates microRNAs as potential treatment strategy for ovarian cancer

Simple molecular sensor color test to determine safe fluoride levels

Simple molecular sensor color test to determine safe fluoride levels

Spectrum's FUSILEV sNDA accepted by FDA for review

Spectrum's FUSILEV sNDA accepted by FDA for review